LAUREN MCMANAMAY: Open Payments
NPI 1932884491 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,503 in 113 payments from 17 companies in 2025. Trend: 2023 $612 · 2024 $2,403 · 2025 $2,503
Food & beverage: $2,503
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $454 |
| Alkermes, Inc. | 10 | $221 |
| Vanda Pharmaceuticals Inc. | 8 | $211 |
| ABBVIE INC. | 16 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $194 |
| E.R. Squibb & Sons, L.L.C. | 11 | $186 |
| Axsome Therapeutics, Inc. | 7 | $182 |
| Biogen, Inc. | 3 | $177 |
| Janssen Pharmaceuticals, Inc | 6 | $166 |
| Collegium Pharmaceutical, Inc. | 6 | $107 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, ARISTADA, FANAPT, COBENFY, Auvelity, ZURZUVAE.
Industry payments across VA — which companies pay providers there.
